TURKU, FINLAND / ACCESS Newswire / January 13, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Jurriaan Dekkers, Chief Financial Officer of the Company, sold 4,000 ordinary shares in Faron at price of £1.822 per share on 12 January 2026.
Further details are set out in the Notification of Dealing Form below.
PDMR | Holding prior to sale | Number of ordinary shares sold | Resultant interest in ordinary shares in the Company | Resultant percentage of voting rights in the Company |
Jurriaan Dekkers | 4,000 | 4,000 | 0 | 0.0% |
For more information, please contact:
IR Partners, Finland |
|
FINN Partners, US | +1 847 791-8085 |
Cairn Financial Advisers LLP | +44 (0) 207 213 0880 |
Sisu Partners Oy | +358 (0)40 555 4727 |
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a. | Name | Jurriaan Dekkers | |||
2 | Reason for notification |
| |||
a. | Position/Status | Chief Financial Officer | |||
b. | Initial notification/ | Initial Notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a. | Name | Faron Pharmaceuticals Ltd. | |||
b. | LEI | 7437009H31TO1DC0EB42 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a. | Description of the financial instrument, type of instrument | Ordinary Shares | |||
b. | Nature of the transaction | Sale of Ordinary Shares | |||
|
|
| Price(s) per share (p) | Volume(s) |
|
£1.822 | 4,000 |
| |||
| |||||
d. | Aggregated information |
| |||
e. | Date of the transaction | 12/01/2026 | |||
f. | Place of the transaction | London Stock Exchange, AIM | |||
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/faron-pharmaceuticals-ltd-pdmr-dealing-1126695
